NVS — NOVARTIS AG ADR (Healthcare >> Drug Manufacturers - General)
NVS FAQ
What is NVS's P/E ratio?
NOVARTIS AG ADR (NVS) currently trades at a P/E ratio of 20.23.
What is NVS's ROE?
NOVARTIS AG ADR reports a Return on Equity (ROE) of 35.14%.
What is NVS's dividend yield?
NOVARTIS AG ADR offers a dividend yield of 3.30%.
What is NVS's Deepscope Quality Score?
Deepscope rates NVS's overall financial quality at 92 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NVS?
Deepscope's AI Timing Score for NVS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NVS belong to?
NOVARTIS AG ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.
|
USD 143.66
Price
4.74
(3.30%)
Day Change
|
|
|---|
NVS, the overall quality is excellent ( Quality = 92) but the timing to buy is ...(Sign In to See)...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROA is too relatively low compare to ROE
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
798
|
| Magic Formula Rank by ROE |
798
|
| Magic Formula Rank by ROIC |
1033
|
| Price | 143.66 |
| PBV / Sector |
7.03 / 2.77
|
| Earning Per Share | 7.10 |
| PE / Sector |
20.23 / 23.60
|
| PEG or PE/Growth / Sector |
0.47 / 0.07
GOOD
|
| Average 1M Daily Value |
192.94 M
GREAT
|
| Average 1W Daily Value |
257.30 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
56% |
| Ability to Make Profit |
|
79% |
| Return to Investors |
|
33% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:30 |
| Symbol | NVS |
| Name | NOVARTIS AG ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 1,908.09 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 273,773.02 / 232,396.15 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Lichtstrasse 35, Basel, Switzerland, 4056
Phone: 41 61 324 11 11
Website: https://www.novartis.com
Employees: 75,267
Description: Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google